BCRX
BioCryst Pharmaceuticals Inc
8.20$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -163.2% | – | – | +0.8% | +563.2% | -122.5% | – | – | |
| – | +0.7% | -27.7% | +4.6% | -2.8% | -0.6% | +7.1% | -0.6% | +1.8% | +1,107.2% | -73.8% | -51.6% | – | |
| – | +34.3% | -17.2% | -3.5% | +30.9% | +23.7% | +0.1% | -0.3% | -12.7% | +290.1% | -77.9% | -8.3% | – | |
| – | – | -368.1% | – | – | – | – | – | -157.6% | – | -1,789.2% | – | – | |
| – | -43.9% | -57.6% | -34.0% | -61.9% | +1,044.1% | -78.8% | +25.2% | +650.8% | -40.3% | -49.8% | -48.1% | – | |
| – | -223.2% | – | -108.5% | – | +109.6% | +52.2% | +7.5% | -53.4% | -715.1% | +221.8% | -59.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -36.0% | +44.9% | +13,474.4% | -33.1% | +294.0% | – | -100.1% | – | |
| – | -359.0% | -67.0% | +87.6% | – | -415.6% | – | -14,029.3% | -20.2% | +243.5% | – | -102.7% | – | |
| – | -952.0% | – | – | – | -61.5% | -92.3% | -3,138.7% | – | – | – | -120.6% | – | |
| – | – | – | – | – | -171.9% | – | – | -2.0% | +583.3% | -122.7% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.